Business Case

Assessed new pain portfolio product lines, for potential update in the Middle East, Central America, and North Africa.

Our client, a large, international pharmaceutical company, possessed a robust portfolio of non-opiate pain products and was looking for strategies to reach additional patients in need of therapy. LSC was engaged to evaluate several strategies for their potential to generate value for customers and maximize the portfolio’s value to our client. The result was a robust report detailing the potential impact of prioritized strategies, such as new formulations, partnerships with healthcare systems, and potential diagnostic campaigns, and ultimately facilitating our client’s life cycle strategy in several emerging markets.